PharmaMar: all 67 studies

Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced MalignanciesNot yet recruitingNCT07839819Phase 1/2
• Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced MalignanciesRecruitingNCT07644039Phase 1/2
• Clinical Trial of PM54 in Advanced Solid Tumors Patients.RecruitingNCT05841563Phase 1
• PM534 Administered Intravenously to Patients With Advanced Solid TumorsRecruitingNCT05835609Phase 1
• Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic ImpairmentRecruitingNCT05101265Phase 1
• Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)TerminatedNCT05705167Phase 2Results posted
• Safety Study of Tivanisiran to Treat Dry EyeCompletedNCT05310422Phase 3Results posted
• Extension Study in a Cohort of Adult Patients With COVID-19 InfectionCompletedNCT05121740Phase 1/2Results posted
• Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid TumorsCompletedNCT05072106Phase 1Results posted
• Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid TumorsCompletedNCT05063318Phase 1Results posted
• Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 InfectionTerminatedNCT04784559Phase 3Results posted
• Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19CompletedNCT04382066Phase 1Results posted
• Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard TreatmentCompletedNCT03427268Phase 2Results posted
• Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and LenalidomideTerminatedNCT03117361Phase 2Results posted
• A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell LymphomaTerminatedNCT03070964Phase 2Results posted
• Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) PatientsCompletedNCT02825420Results posted
• Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung CancerCompletedNCT02566993Phase 3Results posted
• Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid TumorsCompletedNCT02533674Phase 1Results posted
• Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid TumorsCompletedNCT02454972Phase 2Results posted
• Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid TumorsCompletedNCT02451007Phase 2Results posted
• Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer PatientsCompletedNCT02421588Phase 3Results posted
• SYL040012, Treatment for Open Angle GlaucomaCompletedNCT02250612Phase 2Results posted
• Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple MyelomaCompletedNCT02100657Phase 1Results posted
• Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid TumorsCompletedNCT01970540Phase 1Results posted
• A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) PatientsCompletedNCT01951157Phase 2Results posted
• Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid TumorsCompletedNCT01831089Phase 1Results posted
• A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast CancerCompletedNCT01525589Phase 2Results posted
• Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of ChemotherapyCompletedNCT01222767Phase 2Results posted
• Clinical Trial of Aplidin® in Patients With Primary MyelofibrosisCompletedNCT01149681Phase 2Results posted
• Aplidin - Dexamethasone in Relapsed/Refractory MyelomaCompletedNCT01102426Phase 3Results posted
• Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic ChemotherapyTerminatedNCT00900562Phase 2Results posted
• Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin LymphomaCompletedNCT00884286Phase 2Results posted
• A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate CancerTerminatedNCT00780975Phase 2Results posted
• Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory LeukemiaTerminatedNCT00780143Phase 1/2Results posted
• A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or LymphomaTerminatedNCT00359294Phase 1Results posted
• A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple MyelomaCompletedNCT00229203Phase 2Results posted
• Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)Active, not recruitingNCT06088290Phase 3
• A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT05637255Phase 2
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)CompletedNCT05153239Phase 3
• PM14 Administered Intravenously to Patients With Advanced Solid TumorsCompletedNCT05076396Phase 1
• Tivanisiran for Dry Eye in Subjects With Sjögren's SyndromeCompletedNCT04819269Phase 3
• Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye DropsCompletedNCT04782271Phase 1
• HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)CompletedNCT03108664Phase 3
• Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsCompletedNCT02611024Phase 1/2
• Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular PainCompletedNCT02455999Phase 2
• Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue SarcomaCompletedNCT02367924
• Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).CompletedNCT02210364Phase 1
• Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid TumorsCompletedNCT01980667Phase 1
• Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid TumorsCompletedNCT01970553Phase 1
• An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian CancerCompletedNCT01869400
• Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular PainCompletedNCT01776658Phase 1/2
• Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle GlaucomaCompletedNCT01739244Phase 2
• Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy VolunteersCompletedNCT01438281Phase 1
• Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 WeeksCompletedNCT01405391Phase 1
• Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease PatientsCompletedNCT01350362Phase 2
• Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic SyndromeCompletedNCT01314599Phase 1
• Study of PM060184 in Patients With Advanced Solid TumorsCompletedNCT01299636Phase 1
• Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or IfosfamideCompletedNCT01299506
• SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm HgCompletedNCT01227291Phase 1/2
• Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyCompletedNCT01049399Not applicable
• Tolerance and Effect on Intraocular Pressure After Administration of SYL040012CompletedNCT00990743Phase 1
• Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s DiseaseCompletedNCT00948259Phase 1/2
• Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid TumorsCompletedNCT00884845Phase 1
• Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid TumorsCompletedNCT00877474Phase 1
• Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or LymphomasCompletedNCT00788099Phase 1
• A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid TumorsTerminatedNCT00404521Phase 1
• Ecteinascidin 743 in Treating Patients With Malignant MesotheliomaTerminatedNCT00027508Phase 2

← PharmaMar overview and focus areas